Monitoring for Extra-Intestinal Cancers in IBD

被引：12

作者：

Sifuentes H. ^{[1
]}

Kane S. ^{[2
]}

机构：

[1] Department of Gastroenterology and Hepatology, Georgia Regents University, 1120 15th Street, AD 2226, Augusta, 30912, GA

[2] Department of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, 55905, MN

来源：

Current Gastroenterology Reports | 2015年 / 17卷 / 11期

关键词：

Cervical cancer; Cervical dysplasia; Crohn’s disease; Extra-intestinal cancers; Hepatosplenic T cell lymphoma; Inflammatory bowel disease; Lymphoma; Lymphoproliferative disorders; Melanoma; Non-Hodgkin lymphoma; Non-melanoma skin cancer; Ulcerative colitis;

D O I：

10.1007/s11894-015-0467-8

中图分类号：

学科分类号：

摘要：

Multiple studies have demonstrated an increased risk for extra-intestinal cancers in inflammatory bowel disease (IBD) patients, mainly from treatment modalities. Prominent cancers that are related to IBD treatment include the following: lymphoproliferative disorders associated with thiopurine use, hepatosplenic T cell lymphoma primarily in younger male patients on thiopurines and anti-tumor necrosis factor (TNF) agents, non-melanoma skin cancers in patients treated with thiopurines and anti-TNF agents, and melanomas in patients who are on monotherapy with anti-TNF agents. In addition, women with IBD may have higher rates of cervical dysplasia and cervical cancer. The focus of this review is to provide a comprehensive overview on extra-intestinal cancers in IBD patients and how to monitor for these malignancies. © 2015, Springer Science+Business Media New York.

引用

页数：5

共 41 条

[1]

Magro F., Peyrin-Biroulet L., Sokol H., Et al., Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (III), J Crohns Colitis, 8, 1, pp. 31-44, (2014)

[2]

Algaba A., Guerra I., Castano A., Et al., Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease, World J Gastroenterol, 19, 48, pp. 9359-9365, (2013)

[3]

Harwood C.A., Attard N.R., O'Donovan P., Et al., PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients, Br J Cancer, 99, 8, pp. 1276-1284, (2008)

[4]

Munz C., Moormann A., Immune escape by Epstein-Barr virus associated malignancies, Semin Cancer Biol, 18, 6, pp. 381-387, (2008)

[5]

Zitvogel L., Tesniere A., Kroemer G., Cancer despite immunosurveillance: immunoselection and immunosubversion, Nat Rev Immunol, 6, 10, pp. 715-727, (2006)

[6]

Beaugerie L., Itzkowitz S.H., Cancers complicating inflammatory bowel disease, N Engl J Med, 372, 15, pp. 1441-1452, (2015)

[7]

Jones J.L., Loftus E.V., Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?, Inflamm Bowel Dis, 13, 10, pp. 1299-1307, (2007)

[8]

Lewis J.D., Bilker W.B., Brensinger C., Deren J.J., Vaughn D.J., Strom B.L., Inflammatory bowel disease is not associated with an increased risk of lymphoma, Gastroenterology, 121, 5, pp. 1080-1087, (2001)

[9]

Jemal A., Clegg L.X., Ward E., Et al., Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival, Cancer, 101, 1, pp. 3-27, (2004)

[10]

Beaugerie L., Brousse N., Bouvier A.M., Et al., Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, Lancet, 374, 9701, pp. 1617-1625, (2009)

← 1 2 3 4 5 →